Biomerica, Inc. (NASDAQ: BMRA) reported third‑quarter fiscal 2026 results for the quarter ended February 28 2026, showing net sales of $987,000 and a net loss of $1.31 million. Operating expenses were $1.25 million, which produced a net loss per share of $(0.92) for the nine‑month period. Gross margin for the nine‑month period was 13%, down from 15% in the same period a year earlier.
Net sales fell 18% from $1.21 million in the prior quarter, reflecting a decline in contract‑manufacturing revenue and a shift toward lower‑margin product mix. European revenue, however, grew 45% year‑over‑year, driven by new hpdetect orders in the United Kingdom. Real‑world data from the inFoods® IBS segment showed that nearly 60% of patients achieved clinically meaningful pain reduction, underscoring the therapeutic value of the product line.
Gross‑margin compression is attributed to the company’s strategic transition toward higher‑margin diagnostics and a growing Contract Development and Manufacturing Organization (CDMO) services business. CEO Zack Irani said, “We are restructuring Biomerica around higher‑margin, diagnostically‑driven products and a growing CDMO services business — and near‑term revenue reflects that transition. The underlying indicators are encouraging: post‑quarter CDMO customer demand has improved and inFoods® IBS and hp+detect™ represent genuine commercial catalysts. The fixed cost base is established. We expect margin expansion to follow as these initiatives contribute revenue.”
The results illustrate a short‑term revenue dip and margin squeeze, but also signal a pivot toward more profitable business lines. The Medicare payment rate for inFoods® IBS and the rapid European expansion provide new revenue streams that could offset current losses as the higher‑margin mix scales. Investors should view the earnings as a transition period, with potential upside from the company’s diagnostic and CDMO focus, while monitoring the pace of margin recovery.
Overall, Biomerica’s third‑quarter fiscal 2026 earnings reflect a company in the midst of a strategic realignment. The decline in net sales and gross margin highlights near‑term challenges, yet the growth in key segments and management’s confidence in future margin expansion suggest a positive long‑term trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.